Immunotherapy for bladder Ca: What urologists need to know
Peter Black, MD, discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
In the treatment of bladder cancer, the use of newer immunotherapy agents as second-line treatment and in patients who are ineligible for cisplatin-based chemotherapy is “the tip of the iceberg,” according to Peter Black, MD, of the University of British Columbia in Vancouver.
In the near future, look for these agents to be used earlier in the disease process, Dr. Black said.
In this video, Dr. Black discusses which patients are currently eligible for immunotherapy, how the indications are likely to expand, some of the common side effects of immunotherapy and their incidence, and the availability of tools to determine which patients are suitable candidates for treatment.
Dr. Black is a consultant/adviser to GenomeDx Biosciences, Janssen, Astellas, Amgen, Sitka, AbbVie, Bristol Myers Squibb, Bayer, Biosyent, Sanofi, Urogen, and Roche/Genentech. He conducts laboratory research for iProgen.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.
